DENVER, Feb. 14 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation (OTC Bulletin Board: ACLY) announced the introduction of high-performance microtiter plates at the Association of Biomolecular Resource Facilities Annual Meeting in Denver. The new products join the company's line of high-performance OptArray(TM) microarraying slides. The plates and slides both feature the company's proprietary OptiChem(TM) activated surface chemistry. Accelr8 developed the new products in cooperation with Greiner Bio-One GmbH, a German manufacturer of high quality microtiter plates. Under the production agreement, Accelr8 supplies Greiner with OptiChem-coated glass plates. Greiner then bonds the coated glass to their bottomless polystyrene microtiter plate and packages the finished product. The new products are the first to support high performance microarraying applications in the microplate format. Accelr8's early entry into this application space provides an excellent opportunity to capitalize on industry experts' belief that plate-based microarraying is about to provide a new level of interest in gene and protein arraying. Accelr8's product launch is well-timed, as instrument makers are supporting this industry trend by introducing high-volume arraying and plate scanning capabilities. The new plates close a gap in the rollout of plate-based arraying, leveraging the large investments in high throughput plate-handling robotic systems owned by drug discovery laboratories. According to Thomas V. Geimer, Accelr8's CEO and Chairman, "The new product line takes us into specialty areas of the established market for microtiter plates. We're one of the first companies to bring high-performance microarraying to the plate format. OptiChem(TM) delivers the same benefits on a plate as with our OptArray(TM) glass slides. For example, in the area of drug discovery, we believe that our advanced microplate technology will significantly improve data quality and shorten the time to results." He continues, "We're also particularly pleased with our relationship with Greiner Bio-One. They are a leading global supplier of microtiter plates and other laboratory products, and they enjoy a reputation for high quality and excellent service. This relationship demonstrates our commitment to work with market leaders to establish Accelr8's technology in life sciences markets." Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission.
SOURCE Accelr8 Technology Corporation